Bioarctic AB has entered into a research and collaboration agreement with Eli Lilly and Co. on a new treatment in the field of neurodegeneration. The collaboration will see Bioarctic generate a new drug candidate combining its Braintransporter technology with an undisclosed Lilly molecule.